← All trials
NCT03143751
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2017
- Primary completion
- Feb 1, 2020
- Completion date
- Feb 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 370
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of NantesLead sponsor
- University of RennesOverall official - principal investigator
- University of AntwerpOverall official - principal investigator
- University of PoitiersOverall official - principal investigator
- University of ParisOverall official - principal investigator
- University of Western BrittanyOverall official - principal investigator
- University of MontpellierOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- François Rabelais UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.